Gosselies, Belgium, 11 September 2025 (08:30 am CET) – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and ...

Gosselies, Belgium, 11 September 2025 (08:30 am CET) - Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and ...

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bioceres Crop Solutions ( (BIOX)) has ...

VANCOUVER, BC, June 19, 2025 /CNW/ - Freegold Ventures Limited (TSX: FVL) (OTCQX: FGOVF) ("Freegold" or the "Company") is pleased to announce further results from the ongoing metallurgical test work ...

Hello, everyone, and thank you for joining us on today's Bioceres Crop Solutions Fiscal Third Quarter 2025 Financial and Operational Results. My name is Drew and I'll be the operator on today's call.

Bioceres Crop (BIOX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to earnings of $0.14 per share a year ago. These figures ...

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces promising interim results from ...

Bioxodes has stopped enrolling people in a phase 2a stroke study after hitting the safety and efficacy endpoints, positioning the Belgian biotech to power into a potentially registrational trial. The ...

Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations ...